Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient]

[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Abstract Text:

    kazuto oguraKazuto Ogura,takuya machidaTakuya Machida,miho naraMiho Nara,ko mayamaKo Mayama,tomoaki akagiTomoaki Akagi,kohmei kuboKohmei Kubo,kazuto oguraKazuto Ogura,takuya machidaTakuya Machida,miho naraMiho Nara,ko mayamaKo Mayama,tomoaki akagiTomoaki Akagi,kohmei kuboKohmei Kubo,

    Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to calicheamicin, that is rapidly internalized after binding to CD33. This is followed by intracellular release of calicheamicin, which induces double-stranded DNA breaks, cell cycle arrest, and apoptosis. So GO is a more selective agent for acute myeloid leukemia (AML), because the CD33 antigen is expressed on AML, while it is not expressed on normal hematopoietic stem cells and nonhematopoietic tissues. However, some studies indicated that this agent showed resistance to refractory AML cells via various mechanisms, and that there were no potent effects. In this study, we report a 76-year-old female with recurrent AML who responded to single therapy with GO, achieving complete remission for more than 1 year after the start of administration, although additional remission induction was impossible. The response to GO can be stratified with reference to the response to conventional chemotherapy.

    [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Publishing Authors By Initials

    k oguraK Ogura,t machidaT Machida,m naraM Nara,k mayamaK Mayama,t akagiT Akagi,k kuboK Kubo,k oguraK Ogura,t machidaT Machida,m naraM Nara,k mayamaK Mayama,t akagiT Akagi,k kuboK Kubo,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Gan to kagaku ryoho. Cancer & chemotherapy

    VOLUME: 34

    Page Numbers: 1881-3

    Journal Abbreviation: Gan To Kagaku Ryoho

    ISSN: 0385-0684

    DAY: 21

    MONTH: Nov

    YEAR: 2007

    [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Information

    Number of References:

    LANGUAGE: jpn

    NlmUniqueID: 7810034

    [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient]

    AFFILIATION: Dept. of Hematology, Aomori Prefectural Central Hospital.

    Country: Japan

    Japan Research PublicationJapan Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Gan To Kagaku Ryoho

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News